ArriVent BioPharma Appoints New CMOs
Ticker: AVBP · Form: 8-K · Filed: May 16, 2024 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $352,500, $45,000, $235,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
ArriVent BioPharma brings in two new CMOs, Miller and Zelefsky, on May 16, 2024.
AI Summary
On May 16, 2024, ArriVent BioPharma, Inc. announced the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and Dr. Michael J. Zelefsky as Chief Medical Officer. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
The appointment of new Chief Medical Officers signals a potential shift in the company's strategic direction and clinical development focus.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and compensatory arrangements, which are routine corporate events.
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Registrant
- Dr. Jonathan F. Miller (person) — Appointed Chief Medical Officer
- Dr. Michael J. Zelefsky (person) — Appointed Chief Medical Officer
- May 16, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer at ArriVent BioPharma?
Dr. Jonathan F. Miller and Dr. Michael J. Zelefsky have been appointed as Chief Medical Officers.
What is the exact date of this Form 8-K filing?
The Form 8-K was filed on May 16, 2024.
What other information is disclosed in this filing besides executive appointments?
The filing also covers compensatory arrangements of certain officers.
What is the state of incorporation for ArriVent BioPharma, Inc.?
ArriVent BioPharma, Inc. is incorporated in Delaware.
What is the primary business of ArriVent BioPharma, Inc. according to its SIC code?
ArriVent BioPharma, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,106 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2024-05-16 16:11:24
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
- $352,500 — Date"), with a Grant Date fair value of $352,500 (the "Initial Option Award"). The Initi
- $45,000 — d to receive an annual cash retainer of $45,000 for his service as a non-employee direc
- $235,000 — Date"), with a grant date fair value of $235,000 (the "Annual Option Award"). The Annual
Filing Documents
- tm2414720d1_8k.htm (8-K) — 31KB
- tm2414720d1_ex99-1.htm (EX-99.1) — 12KB
- tm2414720d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-24-062528.txt ( ) — 233KB
- avbp-20240516.xsd (EX-101.SCH) — 3KB
- avbp-20240516_lab.xml (EX-101.LAB) — 33KB
- avbp-20240516_pre.xml (EX-101.PRE) — 22KB
- tm2414720d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung, MBA Winston Kung, MBA Chief Financial Officer and Treasurer Date: May 16, 2024